Alnylam spells out its APOLLO-B win for patisiran — but just how good is it?
Alnylam has detailed positive APOLLO-B data for its pivotal trial of patisiran in treating transthyretin-mediated — or ATTR — amyloidosis with cardiomyopathy. And the results spell out a clear advantage over a placebo in preventing a rapid decline in a 6-minute walk test.
But bound to get immediate attention are unanswered questions on the drug’s health benefits and how the drug and placebo data tracked in the study for an increasingly common heart ailment compared to the disaster that befell a rival therapy at BridgeBio. On that score, there was a wild difference between the two studies in the placebo arm, where patients typically see swift deterioration.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,400+ biopharma pros reading Endpoints daily — and it's free.